IP Library Granted Patent US 8,431,557
Granted Patent B2
US 8,431,557 · App. 13/408,760 · Granted Apr 30, 2013

Treatment of menopause-associated symptoms

Inventors: John Brennan (Marietta, GA); Earl E. Sands (Kennesaw, GA); Rex Horton (Marietta, GA); Zurab Bebia (Smyrna, GA)
Assignee: Besins Healthcare Luxembourg SARL
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,431,557
App. No.
13/408,760
Granted
Apr 30, 2013
Kind
B2
Abstract

Described are estradiol-containing pharmaceutical compositions and, and methods using the same to alleviate menopause-related symptoms, such as hot flushes, by topically administering estradiol at low effective doses.

Claims (12)

1. A method of alleviating at least one menopause-associated symptom in a female patient in need thereof, comprising topically administering to said patient an amount of a composition comprising estradiol effective to administer an estradiol dose of about 0.25-0.42 mg/day, wherein the composition is a hydroalcoholic gel that comprises (i) about 0.025-0.035% (w/w) estradiol, (ii) about 0.1-1.5% (w/w) gelling agent, (iii) about 30-50% (w/w) C2-C6 alcohol, and (iv) water.

2. The method of claim 1 , wherein the estradiol dose is about 0.35-0.40 mg/day.

3. The method of claim 1 , wherein the estradiol dose is about 0.375 mg/day.

4. The method of claim 1 , wherein the menopause-associated symptom is selected from the group consisting of vasomotor symptoms, vulvar atrophy, vaginal atrophy, and combinations thereof.

5. The method of claim 1 , wherein the menopause-associated symptom is hot flushes.

6. The method of claim 1 , wherein the method is effective to achieve at least one effect selected from the group consisting of decreasing the severity of vasomotor symptoms, decreasing the frequency of vasomotor symptoms, decreasing the severity of vulvar atrophy, decreasing the severity of vaginal atrophy, and combinations thereof.

7. The method of claim 1 , wherein the gelling agent comprises at least one polyacrylic acid.

8. The method of claim 7 , wherein the gelling agent comprises at least one carbomer.

9. The method of claim 1 , wherein the composition comprises (i) about 0.03% (w/w) estradiol, (ii) about 0.5-1% (w/w) polyacrylic acid polymer, (iii) about 40% (w/w) absolute ethanol, and (iv) water.

10. The method of claim 1 , wherein the composition is a hydroalcoholic gel that comprises (i) about 0.03% (w/w) estradiol; and (ii) about 40% (w/w) absolute ethanol, wherein said composition has a Brookfield viscosity at 20° C. of between 30-120 Pa·s.

11. The method of claim 10 , wherein said Brookfield viscosity is 35-100 Pa·s.

12. The method of claim 10 , wherein said Brookfield viscosity is 50-60 Pa·s.

Assignments (3)
CHANGE OF ADDRESS Recorded Jul 29, 2015
From: BESINS HEALTHCARE LUXEMBOURG SARL
To: BESINS HEALTHCARE LUXEMBOURG SARL
Reel/Frame 036206/0086 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2013
From: BRENNAN, JOHN; SANDS, EARL E.; HORTON, REX; BEBIA, ZURAB
To: BESINS HEALTHCARE
Reel/Frame 029762/0509 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2013
From: BESINS HEALTHCARE
To: BESINS HEALTHCARE LUXEMBOURG SARL
Reel/Frame 029762/0573 →
Continuity (3)
Division 11783889 · Apr 12, 2007
Provisional Application 60791456 · Apr 13, 2006
Related Publication 20120157424A1 · Jun 21, 2012